Tianjin Hospital

Varus-posteromedial rotatory instability (VPMRI) of the elbow is a relatively uncommon yet significant injury that can often present with subtle clinical symptoms, such as mild joint misalignment. These initial symptoms may be easily overlooked or misdiagnosed, especially in the absence of overt signs of instability. As a result, the injury is frequently missed in early stages, leading to improper or delayed treatment. If left untreated, VPMRI can result in severe long-term complications, including rapid joint degeneration, traumatic arthritis, heterotopic ossification, elbow stiffness, and ulnar nerve entrapment. The progressive nature of these issues can lead to permanent functional impairment and reduced quality of life.

A comprehensive literature review was performed to investigate the study objective.

By examining both conservative and surgical interventions, the review provides a comprehensive understanding of this injury, emphasizing the importance of early diagnosis and appropriate management. Understanding the specific forces involved, such as axial loading, varus stress, and forearm pronation, is crucial for developing effective treatment strategies.

Early intervention can prevent long-term complications and improve functional outcomes, making timely and accurate diagnosis essential for optimal care.

Osteosarcoma, a prevalent age-related condition, often goes undiagnosed due to expensive and invasive detection methods. This study presents a novel, cost-effective, non-invasive electrochemical sensor for Osteosarcoma detection, leveraging peptide probes to selectively recognize key biomarkers like iron ions and osteocalcin. Using a phospholipid monolayer and a conductive substrate, the sensor utilizes peptide probes containing a tripeptide iron-binding sequence and an osteocalcin sequence to detect ferroptosis-induced iron ions and elevated osteocalcin levels, both indicative of early-stage Osteosarcoma. Electrochemical modulation facilitates the covalent assembly of osteocalcin into nanoscale aggregates, significantly amplifying the sensor's signal. This design avoids the need for complex antibodies or nanomaterials, enhancing affordability and simplicity. By integrating everyday components like toothpaste to form a low baseline signal and utilizing saliva as the sample, the sensor offers high sensitivity and a low-cost alternative to traditional diagnostic methods. This innovative approach combines bioinspired materials and electrochemical techniques to provide a promising solution for early Osteosarcoma detection, addressing the pressing need for accessible diagnostics in aging populations.

To date, monthly oral bisphosphonates have not been available in China. In this randomized, double blind, positive-controlled, multicenter phase III clinical trial, we compared the efficacy and safety of monthly minodronate versus weekly alendronate in the treatment of Chinese postmenopausal women with osteoporosis. A total of 548 participants were screened across 31 study centers, of which 330 participants were randomized into two groups: the experimental group (n = 165) received oral minodronate (50 mg/tablet once every four weeks) and alendronate placebo (once weekly), while the positive control group (n = 165) received oral alendronate (70 mg/tablet once weekly) and minodronate placebo (once every four weeks) for a duration of 48 weeks. The bone mineral density (BMD) of the lumbar spine, femoral neck and total hip were measured using dual-energy X-ray absorptiometry (DXA) at baseline and at 24 and 48 weeks. At the end of treatments, the experimental group exhibited a mean increase (SD) in BMD above the baseline at the lumbar spine, femoral neck and total hip of 4.61% (4.613%), 3.04% (4.034%) and 3.40% (3.569%), respectively, compared with those of 4.55% (3.753%), 1.86% (3.592%) and 2.30% (4.838%) in the control group. All improvements from the baseline in the two groups were statistically significant. The monthly minodronate did not cause new safety risks compared with alendronate. This study demonstrates that monthly minodronate administration is non-inferior to weekly alendronate in terms of therapeutic efficacy, while maintaining a comparable safety profile. Furthermore, the monthly dosing schedule of minodronate may significantly enhance medication adherence among osteoporosis patients, potentially improving long-term treatment outcomes.